Clinical trials: Rivaroxaban
Venous Thrombosis
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous…
- Trial name
- SATORI (NCT01805544)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- Bayer
Atrial Fibrillation
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia
This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.
- Trial name
- XANAP (NCT01750788)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 11 sites in Hong Kong, India and 9 more
- Volunteers
- 2,297 people
- Sponsor
- Bayer
Anticoagulants; Increased
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
Randomized pilot trial of restarting DOACs at 1 week versus 4 weeks after traumatic intracranial hemorrhage
- Trial name
- NCT04891861
- Testing
- Apixaban
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2
The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 2 (NCT02371070)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
-Rivaroxaban is factor Xa inhibitor
- Trial name
- NCT03193502
- Testing
- rivaroxaban
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
COVID-19
Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on D1 to D7) and Azithromycin (500 mg on D1…
- Trial name
- DOXYCOV (NCT04715295)
- Testing
- Doxycycline Tablets, Rivaroxaban 15Mg Tab, Hydroxychloroquine and Azithromycin
- Where
- Cameroon
- Volunteers
- 200 people
- Sponsor
- Yaounde Central Hospital
Acute Ischemic Stroke, Atrial Fibrillation
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and…
- Conditions
- Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid, Intracranial Atherosclerosis
- Trial name
- ALLY (NCT06058130)
- Testing
- Anticoagulant Oral, Anticoagulation combined with antiplatelet therapy
- Where
- 2 sites in China
- Volunteers
- 2,171 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Bioequivalence
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 20 mg film-coated tablets) or the test…
- Trial name
- NCT04729998
- Testing
- Rivaroxaban film-coated tablet 20 mg, Xarelto® film-coated tablet 20 mg
- Where
- Russia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Chronic Kidney Disease, Acute Bleeding
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
Patients with severe chronic kidney disease (CKD) who develop atrial fibrillation are at high risk for stroke. The use of blood thinking medication in dialysis patients is controversial and warfarin carries a serious risk for…
- Conditions
- Chronic Kidney Disease, Acute Bleeding, Cerebrovascular Stroke
- Trial name
- STOP-HARM (NCT02885545)
- Testing
- Watchman, Continued therapy with the prescribed oral anticoagulant
- Where
- Canada
- Sponsor
- Population Health Research Institute
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Renal Insufficiency
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic…
- Trial name
- VERDICT (NCT02664155)
- Testing
- Apixaban, Rivaroxaban, Heparin
- Where
- 31 sites in France
- Volunteers
- 203 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cervical Artery Dissection
Antithrombotic Treatment Strategies in Cervical Artery Dissection
The goal of this clinical randomised controlled trial is to compare two treatment strategies - antiplatelet treatment strategy versus anticoagulation treatment strategy - in patients with acute, ischemic Cervical Artery…
- Trial name
- TREAT-CAD 2 (NCT07639892)
- Testing
- Antiplatelet Treatment Strategy, Anticoagulation Treatment Strategy
- Volunteers
- 1,100 people
- Sponsor
- University Department of Geriatric Medicine FELIX PLATTER
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Atrial Fibrillation
Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation
We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data
- Trial name
- NCT03108872
- Testing
- left atrial appendage occlusion, New oral anticoagulants
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sejong General Hospital
Venous Thrombosis, Neoplasms
Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis
The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible.
- Trial name
- NCT01999179
- Testing
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Medical College of Wisconsin
Hypotension
Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy
One in ten patients on rivaroxaban therapy have dizziness and reductions in blood pressure. The investigators intend to monitor the ambulatory blood pressure of such patients in order to assess whether this is a true haemodynamic…
- Trial name
- NCT02539953
- Testing
- Ambulatory blood pressure monitoring
- Where
- United Kingdom
- Sponsor
- King's College Hospital NHS Trust
Venous Thrombosis
Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
- Trial name
- EINSTEINJunior (NCT01684423)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 64 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Coronary Artery Ectasia
Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia
The optimal anti-thrombotic therapy to prevent recurrent ischemic events in patients with acute coronary syndrome and coronary artery ectasia (CAE) remains unclear.
- Trial name
- OVER-TIME (NCT05233124)
- Testing
- Rivaroxaban 15 MG, Acetylsalicylic acid 100mg, Clopidogrel 75 Mg Oral Tablet
- Where
- 2 sites in Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Ischemic Stroke, Intracranial Atherosclerosis
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis.
- Conditions
- Ischemic Stroke, Intracranial Atherosclerosis, Stenosis
- Trial name
- AA-ICAS (NCT05700266)
- Testing
- Rivaroxaban, Clopidogrel, Aspirin
- Volunteers
- 1,180 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pharmacokinetics
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders.Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT02367027
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer